Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#354 Risk Stratification Using Octreotide Test For Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results Of Prospective Validation Of The Test

Introduction: Criteria for treatment with somatostatin analogs (SSAs) of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are presence of somatostatin receptors, a positive Octreoscan® or hormonal decrement >50% after octreotide s.c. injection (octreotide test, OT). We demonstrated that a plasma CgA decrement >/=30% after OT is a selection criterion able to predict the clinical response to SSAs.

Conference:

Presenting Author:

Authors: Rossi R, Massironi S, Spampatti M, Conte D, Ciafardini C,

Keywords: octreotide test, somatostatin analogs,

#305 Risk Stratification Using Octreotide Test for Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results of Prospective Validation of the Test

Introduction: We recently demonstrated that a plasma CgA decrement >30% after octreotide s.c. injection is a simple criterion for treatment with Somatostatin analogues (SSA) of gastroenteropancreatic endocrine tumors.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Massironi S, Spampatti M, Rossi R, Conte D, Ciafardini C,

Keywords: gastroenteropancreatic neuroendocrine tumors (GEP-NETs), octreotide test (OT), prognosis ,

#11 Plasma chromogranin - A response to octreotide test: Prognostic value for clinical outcome in endocrine digestive tumors

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) expressing somatostatin receptors may be treated with somatostatin analogues (SSAs). Selection criteria are a positive Octreoscan® or a >50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). Plasma chromogranin A (CgA) is the best general GEP-NET marker, but data on CgA response to OT are scant.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Massironi S

Authors: Massironi S, Conte D, Sciola V, Spampatti M, Rossi R,

Keywords: gastroenteropancreatic neuroendocrine tumors, carcinoids, pancreatic endocrine tumors, chromogranin A, somatostatin analogues,